Key result
Edoxaban peri-procedural management in elderly patients with atrial fibrillation is associated with a low risk of bleeding and thromboembolic complications, with corrected EHRA bleeding risk-low values provided in this erratum.
Why the study?
Does peri-procedural management of edoxaban oral anticoagulation therapy reduce bleeding and thromboembolic complications in elderly patients with atrial fibrillation in routine clinical practice?
Observational
Yes
Does peri-procedural management of edoxaban oral anticoagulation therapy reduce bleeding and thromboembolic complications in elderly patients with atrial fibrillation in routine clinical practice?
This is a correction to a previously published article regarding EHRA bleeding risk values.
May support edoxaban peri-procedural use in elderly AF; leaves open need for randomized confirmation.
An amendment to this paper has been published and can be accessed via the original article.
No takes yet. Share an insight, caveat, or question.
Unverdorben et al. (2021) conducted an observational in Atrial fibrillation. Edoxaban was evaluated. Edoxaban peri-procedural management in elderly patients with atrial fibrillation is associated with a low risk of bleeding and thromboembolic complications, with corrected EHRA bleeding risk-low values provided in this erratum.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: